Literature DB >> 17852013

RANTES levels are elevated in serum and cerebrospinal fluid in patients with amyotrophic lateral sclerosis.

Michael Rentzos1, Chryssoula Nikolaou, Antonis Rombos, Fotini Boufidou, Margarita Zoga, Antonis Dimitrakopoulos, Anthousa Tsoutsou, Demetrios Vassilopoulos.   

Abstract

Immunological disturbances have been implicated in the pathogenesis of amyotrophic lateral sclerosis (ALS). Chemokines are involved in the recruitment of immune cells. Regulated upon activation, normal T-cell expressed and secreted (RANTES) is a C-C beta-chemokine with strong chemo-attractant activity for T-lymphocytes and monocytes. We examined serum levels of RANTES in 20 patients with amyotrophic lateral sclerosis (ALS), 14 patients with non-inflammatory neurological disorders (NIND) and 13 control subjects (CTRL) and cerebrospinal fluid (CSF) levels of RANTES in ALS and NIND group patients in order to investigate whether RANTES as index of immune activation is present in ALS patients. Patients with ALS had higher RANTES levels compared with the NIND patients and CTRL subjects (p = 0.005 and p = 0.02, respectively). CSF RANTES levels were also higher compared with the NIND patients (p = 0.007). No correlation of serum and CSF RANTES levels with disease duration was found. These results may suggest an activated microglia induced recruitment of peripheral inflammatory cells to sites of inflammation in ALS patients.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17852013     DOI: 10.1080/17482960701419232

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler        ISSN: 1471-180X


  19 in total

Review 1.  Systems biology of neurodegenerative diseases.

Authors:  Levi B Wood; Ashley R Winslow; Samantha Dale Strasser
Journal:  Integr Biol (Camb)       Date:  2015-07       Impact factor: 2.192

Review 2.  Motor neuron-immune interactions: the vicious circle of ALS.

Authors:  Ana G Barbeito; Pinar Mesci; Séverine Boillée
Journal:  J Neural Transm (Vienna)       Date:  2010-06-15       Impact factor: 3.575

3.  Efficacy of thalidomide for the treatment of amyotrophic lateral sclerosis: a phase II open label clinical trial.

Authors:  Elijah W Stommel; Jeffrey A Cohen; Camilo E Fadul; Christopher H Cogbill; David J Graber; Linda Kingman; Todd Mackenzie; Jacqueline Y Channon Smith; Brent T Harris
Journal:  Amyotroph Lateral Scler       Date:  2009 Oct-Dec

Review 4.  Microglia in ALS: the good, the bad, and the resting.

Authors:  Jenny S Henkel; David R Beers; Weihua Zhao; Stanley H Appel
Journal:  J Neuroimmune Pharmacol       Date:  2009-12       Impact factor: 4.147

Review 5.  Neuroimmunity dynamics and the development of therapeutic strategies for amyotrophic lateral sclerosis.

Authors:  Melissa Bowerman; Thierry Vincent; Frédérique Scamps; Florence E Perrin; William Camu; Cédric Raoul
Journal:  Front Cell Neurosci       Date:  2013-11-19       Impact factor: 5.505

6.  Correlation between serum RANTES levels and the severity of Parkinson's disease.

Authors:  Peng Tang; Li Chong; Xiaoqing Li; Yue Liu; Peng Liu; Chen Hou; Rui Li
Journal:  Oxid Med Cell Longev       Date:  2014-12-22       Impact factor: 6.543

7.  Effects of facial nerve axotomy on Th2- and Th1-associated chemokine expression in the facial motor nucleus of wild-type and presymptomatic mSOD1 mice.

Authors:  Derek A Wainwright; Junping Xin; Nichole A Mesnard; Christine M Politis; Virginia M Sanders; Kathryn J Jones
Journal:  J Neuroimmunol       Date:  2009-10-08       Impact factor: 3.478

8.  Adaptive immune neuroprotection in G93A-SOD1 amyotrophic lateral sclerosis mice.

Authors:  Rebecca Banerjee; R Lee Mosley; Ashley D Reynolds; Alok Dhar; Vernice Jackson-Lewis; Paul H Gordon; Serge Przedborski; Howard E Gendelman
Journal:  PLoS One       Date:  2008-07-23       Impact factor: 3.240

9.  Complex Inflammation mRNA-Related Response in ALS Is Region Dependent.

Authors:  Sara Berjaoui; Mónica Povedano; Paula Garcia-Esparcia; Margarita Carmona; Ester Aso; Isidre Ferrer
Journal:  Neural Plast       Date:  2015-08-02       Impact factor: 3.599

10.  Early gene expression changes in spinal cord from SOD1(G93A) Amyotrophic Lateral Sclerosis animal model.

Authors:  Gabriela P de Oliveira; Chrystian J Alves; Gerson Chadi
Journal:  Front Cell Neurosci       Date:  2013-11-18       Impact factor: 5.505

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.